Corrigendum to "CX-F9, a novel RSK2 inhibitor, suppresses cutaneous melanoma cells proliferation and metastasis through regulating autophagy" [Biochem. Pharmacol. 168 (2019), 14-25].

Corrigendum to "CX-F9, a novel RSK2 inhibitor, suppresses cutaneous melanoma cells proliferation and metastasis through regulating autophagy" [Biochem. Pharmacol. 168 (2019), 14-25]. Biochem Pharmacol. 2020 Dec 18;184:114372 Authors: Zhang X, Cai L, Zhao S, Long J, Li J, Wu L, Su J, Ling Zhang J, Tao J, Zhou J, Chen X, Peng C PMID: 33348166 [PubMed - as supplied by publisher]
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Biochem Pharmacol Source Type: research